KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial.

Alpesh Shah, Alvin Estilo, Pamela L Sheridan, Uwa Kalu, Dalei Chen, Denise Chang, Mary Slomkowski, Daniel Lee, Nanco Hefting, Mary Hobart, Saloni Behl, Pedro Such, Malaak Brubaker, George T Grossberg

CNS Drugs 39(10) 1011-1023

PMID40681915
PMCIDPMC12423206
DOI10.1007/s40263-025-01200-9
发表日期2025-07-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:AI 判定为 other。
摘要

摘要

BACKGROUND AND OBJECTIVE: Older adults with dementia are particularly vulnerable to antipsychotic side effects. Brexpiprazole, an atypical antipsychotic, is approved in a number of countries for the treatment of agitation associated with dementia due to Alzheimer's disease. This pooled analysis aimed to evaluate the safety and tolerability of brexpiprazole in this patient population. METHODS: Data were included from three Phase 3, 12-week, randomized, double-blind, placebo-controlled trials and a Phase 3, 12-week, active-treatment extension trial in participants with agitation associated with dementia due to Alzheimer's disease. Safety outcomes included treatment-emergent adverse events (TEAEs), weight change, suicidality, extrapyramidal symptoms, and cognitive dysfunction. Two datasets were considered: a 12-week dataset that pooled data from the three randomized trials for brexpiprazole 0.5-3 mg/day and placebo, and a 24-week dataset that combined data from the parent randomized trial and the extension trial for brexpiprazole 2-3 mg/day. RESULTS: Over 12 weeks, 335/655 (51.1%) participants on brexpiprazole and 178/388 (45.9%) participants on placebo reported ≥ 1 TEAE, which led to discontinuation in 41 (6.3%) and 13 (3.4%) participants, respectively. Headache was the only TEAE with incidence ≥ 5% (brexpiprazole, 50 [7.6%] participants; placebo, 36 [9.3%] participants). The incidences of cerebrovascular TEAEs (brexpiprazole, 0.5%; placebo, 0.3%), cardiovascular TEAEs (3.7%; 2.3%), extrapyramidal symptom-related TEAEs (5.3%; 3.1%), and somnolence/sedation TEAEs (3.7%; 1.8%) were generally similar between treatment groups. Six (0.9%) participants on brexpiprazole and 1 (0.3%) participant on placebo died; causes of death were not considered related to brexpiprazole and were generally in line with those expected in Alzheimer's disease. Over 24 weeks, 110/226 (48.7%) participants on brexpiprazole reported ≥ 1 TEAE, which led to discontinuation in 19 (8.4%) participants. Headache was the only TEAE with incidence ≥ 5% (18 [8.0%] participants). No participants died during the extension trial. Over 12 and 24 weeks, mean changes in weight, suicidality, and extrapyramidal symptoms were minimal, with no worsening of cognition. CONCLUSIONS: Considering pooled data from > 1000 participants on brexpiprazole or placebo, brexpiprazole appears to be generally well tolerated for up to 24 weeks in participants with agitation associated with dementia due to Alzheimer's disease. STUDY REGISTRATION: ClinicalTrials.gov identifiers: NCT01862640, NCT01922258, NCT03548584, NCT03594123.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Trial designs. a With a 30-day post-treatment safety follow-up for participants who did not enter Trial 182. b The trial initially included a fourth treatment arm, brexpiprazole 0.5 mg/day, which was removed (after 20 participants had been randomized to this arm) in response to new information indicating this dose was non-efficacious (the 20 participants were allowed to continue). c This was a two-arm trial; however, within the brexpiprazole arm, participants were further randomized in a 1:2 ratio to 2 mg/day or 3 mg/day. d Trials 283 and 284: Days 1–3, 0.25 mg/day; Days 4–14, 0.5 mg/day; Days 15–28, 1 mg/day; and Day 29 onwards, assigned dose (flexible in 284). Trial 213: Days 1–7, 0.5 mg/day; Days 8–14, 1 mg/day; Days 15–28, 2 mg/day; and Day 29 onwards, assigned dose. e With a 30-day post-treatment safety follow-up. f Participants who received brexpiprazole in Trial 213 continued their previous dose; participants who received placebo in Trial 213 were titrated to brexpiprazole: Days 1–7, 0.5 mg/day; Days 8–14, 1 mg/day; and Day 15 onwards, 2 mg/day. One dose decrease and one dose increase within the 2–3 mg/day range were permitted. MMSE Mini-Mental State Examination, NPI-AA Neuropsychiatric Inventory Agitation/Aggression domain, NPI-NH-AA Neuropsychiatric Inventory−Nursing Home version, Agitation/Aggression domain
非 KM Figure
Fig. 2MMSE score over time (24-week analysis; safety sample). Range 0–30; lower scores indicate greater cognitive impairment [ 24 ]. N -values indicate the number of participants with a measurement at that timepoint. MMSE Mini-Mental State Examination, SD standard deviation
非 KM Figure
Fig. 3Body weight over time, showing ( A ) change from baseline and ( B ) clinically relevant change at any visit (safety sample). N -values in A indicate the number of participants with a measurement at that timepoint and, in B, indicate the number of participants with a measurement at baseline and at least one post-baseline visit. SD standard deviation
非 KM Figure